ライフサイエンスコーパス: Waldenstrom macroglobulinemia

1 ic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

2 from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

3 ificance, smoldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

4 of MyD88, which is mutated in a fraction of Waldenstrom macroglobulinemia.

5 ght-chain amyloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

6 as splenic marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

7 the advances observed in the pathogenesis of Waldenstrom macroglobulinemia.

8 ironment) that regulate tumor progression in Waldenstrom macroglobulinemia.

9 rapeutic targeting, such as interleukin-6 in Waldenstrom macroglobulinemia.

10 patients with heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered seli

11 ymphoma overall, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

12 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of s

13 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachm

14 with splenic marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chroni

15 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic

16 ell lymphoma, diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leuk

17 Adjusted P values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thy

18 early universal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor

19 enetic abnormalities in multiple myeloma and Waldenstrom macroglobulinemia have implications for dise

20 of 6q is identified in 50% of patients with Waldenstrom macroglobulinemia, however.

21 d in 17 patients (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary am

22 Waldenstrom macroglobulinemia is a distinct low-grade ly

23 Waldenstrom macroglobulinemia is a similar disease with

24 = 2.9; 1.9-4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11)

25 ype diffuse large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually at

26 ry, acute myeloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

27 Risks for non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobuli

28 ic leukemia (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone

29 Observations: Waldenstrom macroglobulinemia remains a rare, incurable

30 Following profiling, Waldenstrom macroglobulinemia samples clustered with chr

31 Profiling performed after separation of Waldenstrom macroglobulinemia samples into populations w

32 B-cell morphology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resem

33 ion and survival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

34 en with systemic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was

35 he bone marrow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and compu

36 cil to Fludarabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 cen

37 (IgM) class, which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS

38 ell lymphoproliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocyt

39 Treatment options for patients with Waldenstrom macroglobulinemia (WM) and closely related d

40 both in the understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic op

41 significance (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL am

42 YD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight i

43 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell di

44 265P somatic mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignan

45 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the cluste

46 Waldenstrom macroglobulinemia (WM) cells present with in

47 mbination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediat

48 cal evaluation of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by t

49 ormation about the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly adv

50 elated clones in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functio

51 Waldenstrom macroglobulinemia (WM) is a B-cell disorder

52 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

53 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

54 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm

55 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

56 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

57 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

58 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplas

59 Waldenstrom macroglobulinemia (WM) is a proliferative di

60 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplas

61 Waldenstrom macroglobulinemia (WM) is an incurable low-g

62 Waldenstrom macroglobulinemia (WM) is an incurable low-g

63 Waldenstrom macroglobulinemia (WM) is an incurable low-g

64 Waldenstrom macroglobulinemia (WM) is an incurable lymph

65 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospec

66 Waldenstrom macroglobulinemia (WM) is characterized by w

67 Multilevel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improv

68 ing thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to eit

69 or kappaB activity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

70 nical models, the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly unders

71 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarifi

72 4 years), 34 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment,

73 A whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high freq

74 igh response rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by

75 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

76 gnificance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma ch

77 For Waldenstrom macroglobulinemia (WM), a distinct subtype o

78 Waldenstrom macroglobulinemia (WM), a distinctive subtyp

79 portant information on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzl

80 ed as appropriate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic

81 hemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor ag

82 Waldenstrom macroglobulinemia (WM), an IgM-associated ly

83 resent in approximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-c

84 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were o

85 derstand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody

86 r approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has

87 ic of several B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM i

88 Waldenstrom macroglobulinemia (WM), which has an immunog

89 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

90 ations including MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

91 tigate and report its aberrant activation in Waldenstrom macroglobulinemia (WM).

92 ictate clinical presentation and survival in Waldenstrom macroglobulinemia (WM).

93 atic mutations in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

94 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM).

95 inostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

96 brand syndrome is described in patients with Waldenstrom macroglobulinemia (WM).

97 ytic lymphoma (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

98 rolimus in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

99 tuximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

100 t of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

101 BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

102 study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

103 of patients with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent